MERIDIA CAPSULE

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE

Доступна с:

ABBOTT LABORATORIES, LIMITED

код АТС:

A08AA10

ИНН (Международная Имя):

SIBUTRAMINE

дозировка:

10MG

Фармацевтическая форма:

CAPSULE

состав:

SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE 10MG

Администрация маршрут:

ORAL

Штук в упаковке:

30

Тип рецепта:

Prescription

Терапевтические области:

ANOREXIGENIC AGENTS & RESPIRATORY AND CEREBRAL STIMULANTS, MISCELLANEOUS

Обзор продуктов:

Active ingredient group (AIG) number: 0142562001; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2010-10-12

Характеристики продукта

_MERIDIA_
_®_
_ Product Monograph _
_Page 1 of 46 _
_ _
PRODUCT MONOGRAPH
PR
MERIDIA
®
sibutramine hydrochloride monohydrate
10 mg and 15 mg capsules
Anorexiant / Antiobesity Agent
Abbott Laboratories, Limited
Date of Revision:
8401 Trans-Canada Highway
November 26, 2009
St-Laurent, Qc H4S 1Z1
Submission Control No: 130400
_MERIDIA_
_®_
_ Product Monograph _
_Page 2 of 46 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................6
WARNINGS AND
PRECAUTIONS..................................................................................7
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND
STABILITY..........................................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
................................................................................27
PHARMACEUTICAL
INFORMATION..........................................................................27
CLINICAL
TRIALS..........................................................................................................27
D